Anti Cancer Crizotinib Pharmaceutical Intermediate Crizotinib Powder Crizotinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Crizotinib
• Product Name: Crizotinib
• Name: Crizotinib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Grade
• Specific: COA
• Test Method: HPLC
• CAS No: 877399-52-5
• MW: 450.34
• Mf: C21h22cl2fn5o
• Boiling Point: 599.177
• Melting Point: 197
• Density: 1.475
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kg/Month

Product Description

Anti cancer Crizotinib Pharmaceutical Intermediate Crizotinib Powder Crizotinib

Product Description

Product Datails

Product name	Crizotinib
CAS	877399-52-5
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Crizotinib (trade name Xalkori,) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy inanaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
Treating certain types of lung cancer. It may also be used for other conditions as determined by your doctor.
Crizotinib is a tyrosine kinase inhibitor. It works by preventing the growth of cancer cells.
Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.

Application&Function

Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion genebetween EML4 ('echinoderm microtubule-associated protein-like 4') andALK ('anaplastic lymphoma kinase'), which results in constitutivekinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. The kinase activity of the fusion protein is inhibited by crizotinib. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either theepidermal receptor gene (EGFR) or in the K-Ras gene.The number of new cases of ALK-fusion NSLC is about 9,000 per year in the U.S. and about 45,000 worldwide

1.Treating certain types of lung cancer. It may also be used for other conditions as determined by your doctor.
2.Crizotinib is a tyrosine kinase inhibitor. It works by preventing the growth of cancer cells.
3.Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.
 

Specification